ATE397669T1 - Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase - Google Patents

Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase

Info

Publication number
ATE397669T1
ATE397669T1 AT03761600T AT03761600T ATE397669T1 AT E397669 T1 ATE397669 T1 AT E397669T1 AT 03761600 T AT03761600 T AT 03761600T AT 03761600 T AT03761600 T AT 03761600T AT E397669 T1 ATE397669 T1 AT E397669T1
Authority
AT
Austria
Prior art keywords
drug
hiv
drug resistance
phenotypical
reverse transcriptase
Prior art date
Application number
AT03761600T
Other languages
English (en)
Inventor
Hilde Azijn
Bethune Marie-Pierre T M M De
Johan Vingerhoets
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE397669T1 publication Critical patent/ATE397669T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03761600T 2002-07-01 2003-06-30 Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase ATE397669T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39300502P 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
ATE397669T1 true ATE397669T1 (de) 2008-06-15

Family

ID=30000959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761600T ATE397669T1 (de) 2002-07-01 2003-06-30 Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase

Country Status (7)

Country Link
US (2) US7473524B2 (de)
EP (1) EP1522039B1 (de)
AT (1) ATE397669T1 (de)
AU (1) AU2003251732B2 (de)
CA (1) CA2490764C (de)
DE (1) DE60321466D1 (de)
WO (1) WO2004003223A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1185712B8 (de) * 1999-05-28 2005-10-19 Virco Bvba Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
AU2631602A (en) * 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
ATE397669T1 (de) * 2002-07-01 2008-06-15 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase
WO2004003817A1 (en) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
US9428815B2 (en) * 2007-04-10 2016-08-30 Emory University HIV-1 reverse transcriptase codon deletion and its use in the management and treatment of HIV infections

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US327742A (en) 1885-10-06 Machine for making nuts
DE3235565A1 (de) 1982-09-25 1984-03-29 Boehringer Ingelheim KG, 6507 Ingelheim Piperidinderivate, ihre herstellung und verwendung
JPS5974341A (ja) 1982-10-19 1984-04-26 Nissan Motor Co Ltd 車両用アクセル制御装置
GB2229340B (en) 1989-03-17 1994-02-09 Technophone Ltd Radio telephone system
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
EP0428000A1 (de) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
AU4248593A (en) * 1992-05-14 1993-12-13 Mark Holodniy Polymerase chain reaction assays for monitoring antiviral therapy
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
AU719691B2 (en) 1996-01-26 2000-05-18 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
SK283878B6 (sk) * 1996-01-26 2004-04-06 Virco B.V.B.A. In vitro spôsob určenia HIV chemoterapie HIV pozitívnych pacientov
KR100537153B1 (ko) 1996-01-29 2006-12-15 바이럴러직, 인코퍼레이티드 항바이러스약품감수성및내성그리고항바이러스약물의스크리닝을결정하는방법및조성물
JP3062459B2 (ja) 1996-08-14 2000-07-10 理化学研究所 ポリエステル重合酵素遺伝子及びポリエステルの製造方法
BR9911600A (pt) 1998-05-26 2001-02-13 Virologic Inc Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
AU4673399A (en) 1998-05-28 1999-12-13 Visible Genetics Inc. Use of polymorphisms as a predictor of drug-resistance mutations
ES2604662T3 (es) 1998-06-23 2017-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Ensayo de acondicionamiento físico y métodos para reducir la resistencia del VIH a la terapia
MXPA00012843A (es) 1998-06-24 2002-04-24 Virologic Inc Medios y metodo para verificar la terapia antirretroviral con un inhibidor nucleosico de la transcriptasa inversa y guia de decisiones terapeuticas en el tratamiento del vih/sida.
AU762811B2 (en) 1998-06-24 2003-07-03 Innogenetics N.V. Method for detection of drug-selected mutations in the HIV protease gene
EP1185712B8 (de) * 1999-05-28 2005-10-19 Virco Bvba Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
EP1194587A4 (de) 1999-06-22 2005-07-06 Virologic Inc Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids
WO2000078994A1 (en) 1999-06-23 2000-12-28 The Penn State Research Foundation Compositions and methods for the quantification of sterol biosynthetic flux
WO2001079540A2 (en) * 2000-04-18 2001-10-25 Virco Bvba Methods for measuring drug resistance
WO2001081624A1 (en) 2000-04-20 2001-11-01 Virco Bvba Method for mutation detection in hiv using pol sequencing
US7058616B1 (en) * 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
US20030190603A1 (en) * 2000-06-08 2003-10-09 Brendan Larder Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
CA2422815A1 (en) 2000-09-15 2002-03-21 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU2631602A (en) * 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
ES2321809T3 (es) * 2000-10-20 2009-06-12 Virco Bvba Establecimiento de valores e corte biologicos para predecir la resistencia a la terapia.
JP2002199890A (ja) 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
AU2002223052B2 (en) 2000-11-10 2007-09-20 Eurofins Viralliance, Inc. Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV)
PT1370543E (pt) 2001-02-14 2007-02-28 Tibotec Pharm Ltd Inibidores de protease de vih 2-(amino-substituída)-benzotiazol-sulfonamida de largo espectro
EP1319738A1 (de) * 2001-12-17 2003-06-18 Atofina Research S.A. Modifizierte Polyolefinfasern
WO2004003817A1 (en) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
ATE397669T1 (de) * 2002-07-01 2008-06-15 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase
CA2497979A1 (en) 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
EP1605064A1 (de) 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind.

Also Published As

Publication number Publication date
US7473524B2 (en) 2009-01-06
AU2003251732B2 (en) 2008-09-18
CA2490764A1 (en) 2004-01-08
US8076062B2 (en) 2011-12-13
US20050239053A1 (en) 2005-10-27
AU2003251732A1 (en) 2004-01-19
WO2004003223A3 (en) 2005-02-17
WO2004003223A2 (en) 2004-01-08
EP1522039B1 (de) 2008-06-04
DE60321466D1 (de) 2008-07-17
EP1522039A2 (de) 2005-04-13
CA2490764C (en) 2011-11-22
US20090061420A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
Walter et al. Genomic variant-identification methods may alter Mycobacterium tuberculosis transmission inferences
ATE432506T1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
GB0712154D0 (en) Method for evaluating correlations between structured and normalized information on genetic variations between humans and their personal clinical patient data
ATE397669T1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase
Getaneh et al. Survival and Predictors of Mortality among Adults Initiating Highly Active Antiretroviral Therapy in Ethiopia: A Retrospective Cohort Study (2007‐2019)
Mukherjee et al. Switching between raltegravir resistance pathways analyzed by deep sequencing
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
BR9911600A (pt) Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
Kostaki et al. Validation of molecular clock inferred HIV infection ages: Evidence for accurate estimation of infection dates
Safina et al. Molecular epidemiology of HIV-1 in Oryol oblast, Russia
EP1407042A4 (de) Mittel und verfahren zur überwachung einer antiretroviralen proteaseinhibitortherapie und als richtschnur für therapeutische entscheidungen bei der behandlung von hiv/aids
Magiorkinis et al. An innovative study design to assess the community effect of interventions to mitigate HIV epidemics using transmission-chain phylodynamics
Lasek-Nesselquist et al. A statewide analysis of SARS-CoV-2 transmission in New York
Metsky et al. Capturing diverse microbial sequence with comprehensive and scalable probe design
KR200208239Y1 (ko) 특정인의 ｄｎａ구조를 형상화한 팔찌
GB2520021A (en) HCV genotyping algorithm
Zhao et al. Directional predictions of HIV transmission with optimised genomics in cohorts of serodiscordant couples
Wirden et al. Benefits of HIV‐1 transmission cluster surveillance: a French retrospective observational study of the molecular and epidemiological co‐evolution of recent circulating recombinant forms 94 and 132
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
Guessous et al. Trends in pharmacogenomic epidemiology: 2001–2007
BR0111575A (pt) Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids
DIVERSE Session 1020 (Symposium)
DE60313366D1 (de) Nukleinsäuresonden und Verfahren zum Nachweis einer Zielnukleinsäuresequenz mit zwei oder mehr cis-Nukleinsäurebereichen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1522039

Country of ref document: EP